Reading time is 2 mins


A new drug being studied was the hope for patients by shrinking tumors that cause brain cancer. One patient, 34, who was diagnosed with brain cancer, said he was involved in the research and that his tumor had shrunk by more than 90 percent.

After years of research, doctors have indicated that lisavanbulin, a drug being trialed on British patients, is hope for a cure for brain cancer. The reason for doctors ‘ optimism is the results of an experiment conducted by the Royal Marsden NHS Foundation Trust and the Institute for Cancer Research in London.

One patient, who participated in the experiment, was told he would have less than 12 months to live. His driver’s license was taken away, and he and his wife prepared for the worst outcome. But four years later he is still alive and his results are so good that he has become one of the few brain cancer patients allowed to drive.


Nicholson, whose tumor was the size of his fist and did not respond to standard radiotherapy or chemotherapy, began taking lisavanbulin in May 2018. Nicholson said of his recovery: “there was a 5 per cent chance the drug would work; but incredibly, my scans look good.”

A scan this month revealed that the treatment, which she takes as five tablets every morning, has reduced her tumor by 93 per cent.

Lisavanbulin inhibits the growth and spread of cancer by interfering with certain changes in proteins or genes involved in disease progression.


Dr who manages to work at the Institute for Cancer Research is a clinical researcher who says: “they have a very low survival rate for people with brain cancer and is currently lack of treatment options; therefore, this drug can be extremely limited ammo us a very nice contribution to fight disease.”

Glioblastomas are known as the most common type and most dangerous of high-grade primary brain tumors. They grow fast and have filamentous branches that extend to other parts of the brain. Even if they are treated intensively, they are quite likely to spread and come back. Around 5,000 people are diagnosed with glioblastoma every year in the UK.

In addition, because tumors can mutate quickly, treatments may not be enough. The average survival time after diagnosis ranges from 12 to 18 months, while only 25 percent of glioblastoma patients survive for more than a year.

Direct targeted treatments for brain cancer have not yet been developed, because identifying targets and designing drugs against them requires a huge amount of research. There is also an additional challenge in brain cancer of producing drugs that can cross the blood-brain barrier.


Follow me
President of Organ Transplant Center at MedicalPark Hospital Antalya

Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.

Physician's Resume:

Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.

Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.

In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.


Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.


Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .

Professional Members:

American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.


Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
Medically Reviewed by Professor Doctor Alper Demirbaş
Follow me
Latest posts by Medically Reviewed by Professor Doctor Alper Demirbaş (see all)